2. KDIGO 2012: Clinical practice guideline for the evaluation and management of Chronic kidney disease. URL: http://www.kdigo.org

3. Turin T.С., Tonelli M., Manns B.J., Ravani P., Ahmed S.B., Hemmelgarn B.R. Chronic kidney disease and life expectancy. Nephrol. Dial. Transplant. 2012;27(8):3182–3186. Doi: 10.1093/ndt/gfs052.

4. Matsushita K., Ballew S.H., Coresh J. Cardiovascular risk prediction in people with chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2016;25(6):518–523. Doi: 10.1097/mnh.0000000000000265.

5. O’Seaghdha C.M., Lyass A., Massaro J.M., Meigs J.B., Coresh J., D’Agostino R.B. Sr., Astor B.C., Fox C.S. A risk score for chronic kidney disease in the general population. Am. J. Med. 2012;125:270–277. Doi: 10.1016/j.amjmed.2011.09.009.

6. Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. Методические рекомендации. Под ред. С.А. Бойцова, А.Г. Чучалиной. М., 2014:112 с.

7. McMahon G.M., Preis S.R., Hwang S-J., Fox C.S. Mid-adulthood risk factor profiles for CKD. J. Am. Soc. Nephrol. 2014;25(11):2633–2641. Doi: 10.1681/ASN.2013070750.

8. Plantinga L.C., Boulware L.E., Coresh J., Stevens L.A., Miller E.R. 3rd, Saran R., Messer K.L., Levey A.S., Powe N.R. Patient awareness of chronic kidney disease: Trends and predictors. Arch. Intern. Med. 2008;168(20):2268–2275. Doi: 10.1001/archinte.168.20.2268.

9. Бикбов, Б.Т., Томилина Н.А. Заместительная терапия больных схронической почечной недостаточностью в Российской Федерации в 1998–2011 гг. Нефрология и диализ. 2014;16(1):11–127.

10. Бикбов Б.Т., Томилина Н.А. Раннее выявление хронической болезни почек: маркер преемственности в лечении пациентов, влияние на выживаемость и кардиоваскулярную летальность больных на диализе. Российский медицинский журнал. 2014;1:12–17.

11. Hippisley-Cox J., Coupland C. Predicting the risk of chronic kidney disease in men and women in England and Wales. Prospective derivation and external validation of the Kidney Scores. BMC Fam. Pract. 2010;11:49. Doi: 10.1186/1471-2296-11-49.

12. Fedeli U., De Giorgi A., Gennaro N., Ferroni E., Gallerani M., Mikhailidis D.P., Manfredini R., Fabbian F. Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy. Int. J. Chron. Obstruct. Pulmon. Dis. 2017;12:443–450. Doi:10.2147/COPD.S119390.

13. Dalal A.A., Shah M., D’Souza A.O., Rane P. Costs of COPD in the exacerbations in the emergency department and inpatient setting. Respir. Med. 2011;105(3):454–460. Doi: 10.1016/j.rmed.2010.09.003.

14. Hu G., Zhou Y., Tian J., Yao W., Li J., Li B., Ran P. Risk of COPD from exposure to biomass smoke: a meta-analysis. Chest. 2010;138(1):20–31. Doi: 10.1378/chest.08-2114.

15. Chronic obstructive pulmonary disease (COPD). World Health Organization, 2011. URL: http://www.who.int/respiratory/copd.

16. Tsiligianni I.G., Kosmas E., Van der Molen T., Tzanakis N. Managing comorbidity in COPD: a difficult task. Curr. Drug. Targets. 2013;14(2):158–176.

17. Schnell K., Weiss C.O., Lee T., Krishnan J.A., Leff B., Wolff J.L., Boyd C. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm. Med. 2012;12:26. Doi: 10.1186/1471-2466-12-26.

18. Болотова Е.В., Являнская В.В., Дудникова А.В. Минерально-костные нарушения у больных хронической обструктивной болезнью легких в сочетании с хронической болезнью почек. Клиническая нефрология. 2016;3–4:75–79.

19. Болотова Е.В., Дудникова А.В. Хроническая болезнь почек у пациентов с хронической обструктивной болезнью легких: роль частоты обострений. Пульмонология. 2016;25(5):578–583.

20. VanGestel Y.R., Chonchol M., Hoeks S.E., Welten G.M., Stam H., Mertens F.W., van Domburg R.T., Poldermans D. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. Nephrol. Dial. Transplant. 2009;24(9):2763–2767. Doi: 10.1093/ndt/gfp171.

21. Chen C.-Y., K.-M. Liao. Chronic Obstructive Pulmonary Disease is associated with risk of Chronic Kidney Disease: A Nationwide Case-Cohort Study. Sci Rep. 2016;6:25855. doi: 10.1038/srep25855.

22. Ibrahim I., Elmahallawy А., Qora M.A. Prevalence of chronic renal failure in COPD. Egyptian Journal of Chest Diseases and Tuberculosis. 2013;62:221–227.

23. Eagan T.M., Ueland T., Wagner P.D., Hardie J.A., Mollnes T.E., Damås J.K., Aukrust P., Bakke P.S. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur. Respir. J. 2010;35(3):540–548. Doi: 10.1183/09031936.00088209.

24. Yoshizawa T., Okada K., Furuichi S., Ishiguro T., Yoshizawa A., Akahoshi T., Gon Y., Akashiba T., Hosokawa Y., Hashimoto S. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:1283–1289. Doi: 10.2147/COPD.S80673.

25. Gjerde B., Bakke P.S., Ueland T., Hardie J.A., Eagan T.M. The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. Respir Med. 2012;106(3):361–366. Doi: org/10.1016/j.rmed.2011.10.004.

26. Raman M., Green D., Middleton R.J., Kalra P.A. Оlder people with chronic kidney disease: definition, and influence of biomarkers and medications upon cardiovascular and renal outcomes . J. Ren. Care. 2016;42(3):150–161. Doi: 10.1111/jorc.1216.

27. Yeh Y.C., Huang M.F., Hwang S.J., Tsai J.C., Liu T.L., Hsiao S.M., Yang Y.H., Kuo M.C., Chen C.S. Association of homocysteine level and vascular burden and cognitive function in middle-aged and older adults with chronic kidney disease. Int. J. Geriatr. Psychiatry. 2016;31(7):723–730. Doi: 10.1002/gps.4383.

28. Lee M.H., Ahn S.V., Hur N.W., Choi D.P., Kim H.C., Suh I. Gender differences in the association between smoking and dyslipidemia: 2005 Korean national health and nutrition examination survey. Clin. Chim. Acta. 2011;412(17–18):1600–1605. Doi: 10.1016/j.cca.2011.05.013.

29. Ishani A., Grandits G.A., Grimm R.H., Svendsen K.H., Collins A.J., Prineas R.J., Neaton J.D. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J. Am. Soc. Nephrol. 2006;17(5):1444-52. Doi: 10.1681/asn.2005091012.

30. Grunwald J.E., Alexander J., Ying G-S, Maguire M., Daniel E., Whittock-Martin R., Parker C., McWilliams K., Lo J.C., Go A., Townsend R., Gadegbeku C.A., Lash J.P., Fink J.C., Rahman M., Feldman H., Kusek J.W., Xie D., Jaar B.G.; CRIC Study Group. Retinopathy and chronic kidney disease in the chronic renal insufficiency cohort study (CRIC). Arch. ophthalmol. 2012;130(9):1136–1144. Doi: 10.1001/archophthalmol.2012.1800.

31. Ricardo A.C., Anderson C.A., Yang W., Zhang X., Fischer M.J., Dember L.M., Fink J.C., Frydrych A., Jensvold N.G., Lustigova E., Nessel L.C., Porter A.C., Rahman M., Wright Nunes J.A., Daviglus M.L., Lash J.P.; CRIC Study Investigators. Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the chronic renal insufficiency cohort (CRIC) study. Am. J. Kidney Dis. 2015;65(3):412–424. Doi: 10.1053/j.ajkd.2014.09.016.

32. Chandra D., Stamm J.A., Palevsky М., Leader J.K., Fuhrman C.R., Zhang Y., Bon J., Duncan S.R., Branch R.A., Weissfeld J., Gur D., Gladwin M.T., Sciurba F.C. The relationship between pulmonary emphysema and kidney function in smokers. Chest. 2012;142(3):655–662. Doi:10.1378/chest.11-1456.

33. Alba M.M., Citarelli A.N., Menni F., Agricola M., Braicovich A., De Horta E., De Rosa F., Filanino G., Gaggiotti R., Junqueras N., Martinelli S., Milan A., Morales M.E., Setti S., Villalba D.O. Tobacco and end stage renal disease: a multicenter, cross-sectional study in Argentinian Northern Patagonia. Tob. Induc. Dis. 2015;13(1):28. Doi: 10.1186/s12971-015-0051-x.

34. Bentata Y., Karimi I., Benabdellah N., Alaoui F.E., Haddiya I., Abouqal R. Does smoking increase the risk of progression of nephropathy and/or cardiovascular disease in type 2 diabetic patients with albuminuria and those without albuminuria? Am. J. Cardiovasc. Dis. 2016;18(6):66–69.

35. Maeda I., Hayashi T., Sato K.K., Koh H., Harita N., Nakamura Y., Endo G., Kambe H., Fukuda K. Cigarette smoking and the association with glomerular hyperfiltration and proteinuria in healthy middle-aged men. Clin. J. Am. Soc. Nephrol. 2011;6(10):2462–2469. Doi: 10.2215/CJN.00700111.

36. Gamboa J.L., Billings F.T., Bojanowski M.T., Gilliam L.A., Yu C., Roshanravan B., Roberts L.J. 2nd, Himmelfarb J., Ikizler T.A., Brown N.J. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol. Rep. 2016;4(9):e12780. Doi: 10.14814/phy2.12780.

37. Csonka C., Sárközy M., Pipicz M., Dux L., Csont T. Modulation of Hypercholesterolemia-Induced Oxidative / Nitrative Stress in the Heart. Oxid. Med. Cel. Longev. 2016;16:3863726. Doi: org/10.1155/2016/3863726.

38. Огородова Л.М., Черняк Б.А., Козина О.В., Фрейдин М.Б., Трофименко И.Н., Куликов Е.С., Селиванова П.А. Молекулярно-генетические аспекты различных фенотипов хронической обструктивной болезни легких и бронхиальной астмы. Пульмонология. 2013;1:5–11. Doi: org/10.18093/0869-0189-2013-0-1-5–11.

39. Bagdonas E., Raudoniute J., Bruzauskaite I., Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:995–1013. Doi: 10.2147/COPD.S82518.

40. Malhotra R., Olsson H. Immunology, genetics and microbiota in the COPD pathophysiology: potential scope for patient stratification. Expert. Rev. Respir. Med. 2015;9(2):153–159. Doi: 10.1586/17476348.2015.1000865.

41. Lerner C.A., Sundar I.K., Rahman I. Mitochondrial redox system, dynamics, and dysfunction in lung inflammaging and COPD. Int. J. Biochem. Cell. Biol. 2016;81(Pt. B):294–306. doi: 10.1016/j.biocel.2016.07.026.

42. Sinden N.J., Baker M.J., Smith D.J., Kreft J.U., Dafforn T.R., Stockley R.A. α-1-Antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2015;308(2):L179–L190. Doi: 10.1152/ajplung.00179.2014.

43. King P.T. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin. Transl. Med. 2015;4(1):68. Doi: 10.1186/s40169-015-0068-z.

44. Tuder R.M., Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 2012;122(8):2749–2755. Doi: 10.1172/JCI60324.

45. Domej W., Oettl K., Renner W. Oxidative stress and free radicals in COPD – implications and relevance for treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2014;9:1207–1224. Doi: 10.2147/COPD.S51226.

46. Thomsen M., Dahl M., Lange P., Vestbo J., Nordestgaard B.G. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;186(10):982–988. Doi: 10.1164/rccm.201206-1113OC.

47. Van Eeden S., Leipsic J., Paul Man S.F. The relationship between lung inflammation and cardiovascular disease. Am. J. Respir. Crit. Care Med. 2012; 186(1):11–16. Doi: 10.1164/rccm.201203-0455PP.

48. Divo M., Cote C., de Torres J.P., Casanova C., Marin J.M., Pinto-Plata V., Zulueta J., Cabrera C., Zagaceta J., Hunninghake G., Celli B.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;186(2):155–161. Doi: 10.1164/rccm.201201-0034OC.

49. Fassett R.G., Venuthurupalli S.K., Gobe G.C., Coombes J.S., Cooper M.A., Hoy W.E. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80:806–821. Doi: 10.1038/ki.2011.198.

50. Van Boven J.F., Román-Rodríguez M., Palmer J.F., Toledo-Pons N., Cosío B.G., Soriano J.B. Comorbidome, pattern, and impact of asthma-copd overlap syndrome in real life. Chest. 2016;149(4):1011–1020. Doi: 10.1016/j.chest.2015.12.002.

51. Luttropp K., Debowska M., Lukaszuk T., Bobrowski L., Carrero J.J., Qureshi A.R., Stenvinkel P., Lindholm B., Waniewski J., Nordfors L. Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2016;31(12):2033–2040. Doi: 10.1093/ndt/gfw066.

52. Barakat M., McDonald H., Collier T., Smeeth L., Nitsch D., Quint J.K. Acute kidney injury in stable COPD and at exacerbation. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:2067–2077. Doi: 10.2147/COPD.S88759.

53. Li Х., Wang T., Yang T., et al. Serum triglycerides and high density lipoprotein in patients as a potential modulator of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013;187:A2896.

54. Gunnell D., Whitley E., Upton M.N., McConnachie A., Smith G.D., Watt G.C. Associations of height, leg length, and lung function with cardiovascular risk factors in the Midspan Family Study. J. Epidemiol. Community Health. 2003;57(2):141–146. Doi: 10.1136/jech.57.2.141.

55. Agassandian M., Mallampalli R.K. Surfactant phospholipid metabolism. Biochim. Biophys. Acta. 2013;1831(3):612–625. Doi: 10.1016/j.bbalip.2012.09.010.

56. Lee H.S. Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome. Histol. Histopathol. 2011;26(12):1599–1610. Doi: 10.14670/HH-26.1599.

57. Zager R.A., Johnson A.C., Becker K. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and «end-stage» kidney disease. Am. J. Physiol. Renal. Physiol. 2011;301(6):F1334–F1345. Doi: 10.1152/ajprenal.00431.201.

58. Le Clef N., Verhulst A., D’Haese P.C., Vervaet B.A. Unilateral renal ischemia-reperfusion as a robust model for acute to chronic kidney injury in mice. PLoS One. 2016;11(3):e0152153. Doi: 10.1371/journal.pone.0152153.

59. Bentata Y., Karimi I., Benabdellah N., Alaoui F.E., Haddiya I., Abouqal R. Does smoking increase the risk of progression of nephropathy and/or cardiovascular disease in type 2 diabetic patients with albuminuria and those without albuminuria? Am. J. Cardiovasc. Dis. 2016;18(6):66–69.

60. Vaziri N.D., Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood. Purif. 2011;31(1–3):189–196. Doi: 10.1159/000321845.

61. Vaziri N.D. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J. Ren. Nutr. 2010;20(5 Suppl):35–43. Doi: 10.1053/j.jrn.2010.05.010.

62. Vaziri N.D. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin. Dial. 2009;22(6):644–651. Doi: 10.1111/j.1525-139X.2009.00661.x.

63. Saland J.M., Satlin L.M., Zalsos-Johnson J., Cremers S., Ginsberg H.N. Impaired postprandial lipemic response in chronic kidney disease. Kidney Int. 2016;90(1):172–180. Doi: 10.1016/j.kint.2016.02.031.

64. Otsuka F., Yasuda S., Noguchi T., Ishibashi-Ueda H. Pathology of coronary atherosclerosis and thrombosis. Cardiovasc. Diagn. Ther. 2016;6(4):396–408. Doi: 10.21037/cdt.2016.06.01.

65. Mae S., Shono A., Shiota F., Yasuno T., Kajiwara M., Gotoda-Nishimura N., Arai S., Sato-Otubo A., Toyoda T., Takahashi K., Nakayama N., Cowan C.A., Aoi T., Ogawa S., McMahon A.P., Yamanaka S., Osafune K. Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat. Commun. 2013;4: 367. Doi:10.1038/ncomms2378.

66. Mapel D.W., Dutro M.P., Marton J.P., Woodruff K., Make B. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv. Res. 2011;11:43. Doi: 10.1186/1472-6963-11-43.

67. Болотова Е.В. Дудникова А.В. Хроническая болезнь почек: вклад в коморбидность у пожилых пациентов с хронической обструктивной болезнью легких. Успехи геронтологии. 2016;29(4):628–633.

68. Baptist A.P., Reddy R.C. Inhaled corticosteroids for asthma: are they all the same? J. Clin. Pharm. Ther. 2009;34:1–12. Doi: 10.1111/j.1365-2710.2008.00970.x.